pull down to refresh

The startup developed AI for the design of molecules used to create drugs. Its latest model, Chai 2, has demonstrated a "double-digit success rate" in experiments to create entirely new antibodies.
Chai has raised $225 million since 2024. Its latest valuation is $1.3 billion. OpenAI is one of its major investors.